NASDAQ:ICPT

Intercept Pharmaceuticals Stock Forecast, Price & News

Most-Downgraded Stocks

$27.45

-1.79 (-6.12 %)

(As of 01/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$27.01

Now: $27.45▼

$28.40

50-Day Range

$24.48

MA: $30.49▼

$37.27

52-Week Range

$23.78

Now: $27.45▼

$114.32

Volume2.58 million shs

Average Volume1.21 million shs

Market Capitalization$905.58 million

P/E RatioN/A

Dividend YieldN/A

Beta1.85

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. It has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China; and Aralez Pharmaceuticals Canada Inc to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.

MarketRank^™

Overall MarketRank^™

1.91 out of 5 stars

Medical Sector

68th out of 1,557 stocks

Pharmaceutical Preparations Industry

31st out of 638 stocks

4.1 Analyst's Opinion

Consensus Rating
Intercept Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 8 buy ratings, 15 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $60.22, Intercept Pharmaceuticals has a forecasted upside of 119.4% from its current price of $27.45.
Amount of Analyst Coverage
Intercept Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.1 Community Rank

Outperform Votes
Intercept Pharmaceuticals has received 1,032 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Intercept Pharmaceuticals has received 649 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Intercept Pharmaceuticals has received 61.39% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote “Outperform” if you believe ICPT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ICPT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Intercept Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Intercept Pharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Intercept Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $111,454.00 in company stock.
Percentage Held by Insiders
Only 23.70% of the stock of Intercept Pharmaceuticals is held by insiders.
Percentage Held by Institutions
85.77% of the stock of Intercept Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Intercept Pharmaceuticals are expected to grow in the coming year, from ($8.23) to ($6.63) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Intercept Pharmaceuticals is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Intercept Pharmaceuticals is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Intercept Pharmaceuticals has a P/B Ratio of 17.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:ICPT

Previous Symbol

CUSIP45845P10

CIK1270073

Webwww.interceptpharma.com

Phone646-747-1000

Employees583

Debt

Debt-to-Equity RatioN/A

Current Ratio3.44

Quick Ratio3.44

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$252 million

Price / Sales3.59

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.57 per share

Price / Book17.48

Profitability

EPS (Most Recent Fiscal Year)($10.89)

Net Income$-344,680,000.00

Net Margins-106.64%

Return on Equity-1,973.10%

Return on Assets-48.51%

Miscellaneous

Outstanding Shares32,990,000

Market Cap$905.58 million

Next Earnings Date2/23/2021 (Estimated)

OptionableOptionable

$27.45

-1.79 (-6.12 %)

(As of 01/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ICPT News and Ratings via Email

Sign-up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter.

Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions

How has Intercept Pharmaceuticals' stock been impacted by Coronavirus?

Intercept Pharmaceuticals' stock was trading at $77.60 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ICPT shares have decreased by 64.6% and is now trading at $27.45.
View which stocks have been most impacted by COVID-19.

Is Intercept Pharmaceuticals a buy right now?

24 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 1 sell rating, 15 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Intercept Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICPT, but not buy additional shares or sell existing shares.
View analyst ratings for Intercept Pharmaceuticals or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Intercept Pharmaceuticals?

Wall Street analysts have given Intercept Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Intercept Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Intercept Pharmaceuticals' next earnings date?

Intercept Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Intercept Pharmaceuticals.

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced its quarterly earnings results on Monday, November, 9th. The biopharmaceutical company reported ($2.01) earnings per share for the quarter, missing the consensus estimate of ($1.96) by $0.05. The biopharmaceutical company had revenue of $79.50 million for the quarter, compared to analysts' expectations of $78.60 million. Intercept Pharmaceuticals had a negative return on equity of 1,973.10% and a negative net margin of 106.64%. Intercept Pharmaceuticals's quarterly revenue was up 28.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($2.59) earnings per share.
View Intercept Pharmaceuticals' earnings history.

What guidance has Intercept Pharmaceuticals issued on next quarter's earnings?

Intercept Pharmaceuticals issued an update on its FY 2020 Pre-Market earnings guidance on Monday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $310-320 million, compared to the consensus revenue estimate of $311.93 million.

What price target have analysts set for ICPT?

24 Wall Street analysts have issued 12 month price targets for Intercept Pharmaceuticals' shares. Their forecasts range from $27.00 to $140.00. On average, they expect Intercept Pharmaceuticals' stock price to reach $60.22 in the next twelve months. This suggests a possible upside of 119.4% from the stock's current price.
View analysts' price targets for Intercept Pharmaceuticals or view Wall Street analyst' top-rated stocks.

Who are some of Intercept Pharmaceuticals' key competitors?

Some companies that are related to Intercept Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Novavax (NVAX).
View all of ICPT's competitors.

What other stocks do shareholders of Intercept Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN) and Biogen (biib).

Who are Intercept Pharmaceuticals' key executives?

Intercept Pharmaceuticals' management team includes the following people:

Mr. Jerome B. Durso, Pres & CEO (Age 53, Pay $953.9k)
Mr. Sandip S. Kapadia CPA, M.B.A., CFO, Treasurer & Principal Accounting Officer (Age 51, Pay $738.4k)
Dr. Mark Pruzanski, Founder, Advisor & Director (Age 53, Pay $1.3M)
Mr. Richard Kim, Pres of U.S. Commercial & Strategic Marketing (Age 52, Pay $987.56k)
Ms. Lisa M. DeFrancesco, VP of Investor Relations
Mr. David Ford, Chief HR Officer (Age 52)
Ms. Lisa Bright Morrison, Pres of International (Age 53)
Dr. Christian Weyer, Exec. VP of R&D (Age 51)
Dr. Gail Cawkwell, Sr. VP of Medical Affairs, Safety & Pharmacovigilance (Age 59)
Dr. Jason A. Campagna, Chief Medical Officer (Age 51)

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

How do I buy shares of Intercept Pharmaceuticals?

Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Intercept Pharmaceuticals' stock price today?

One share of ICPT stock can currently be purchased for approximately $27.45.

How big of a company is Intercept Pharmaceuticals?

Intercept Pharmaceuticals has a market capitalization of $905.63 million and generates $252 million in revenue each year. The biopharmaceutical company earns $-344,680,000.00 in net income (profit) each year or ($10.89) on an earnings per share basis. Intercept Pharmaceuticals employs 583 workers across the globe.

What is Intercept Pharmaceuticals' official website?

The official website for Intercept Pharmaceuticals is www.interceptpharma.com.

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here